To All, Mini Barron's review. Generally, not such a hot issue, but a couple of extraordinary articles that make it well worth the money. 1. A slam on my old buddy, Gliatech, in Abelson's column. I'm long out of it, so, no prob. <g> 2. A great article, "Burning Up," that lists when internut cos. will either need a cash injection or go belly up. The text is no big deal, but the data is great and it is something I've been compiling on my own at great expense of time. This is a keeper. It is nice to know that Amazon will survive for nearly an entire year after its convertible offering. <g>
3. An interview with Alan Carr, the portfolio manager of HQH and HQL, my two favorite biotech CEFs. A great primer in biotech investing.
The rest of the issue is boring crap. |
